Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia

Psychopharmacology

Volumn 231, Issue 4, 2014, Pages 765-775

  Roh, Sungwon ^a   Hoeppner, Susanne S ^a   Schoenfeld, David ^a   Fullerton, Catherine A ^a   Stoeckel, Luke E ^a   Evins, A Eden ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Attention; Cognitive function; Mecamylamine; Nicotine; Schizophrenia; Smoking; Varenicline; Working memory

Indexed keywords

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; BENZAZEPINES; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MECAMYLAMINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; QUINOXALINES; REACTION TIME; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING CESSATION; TASK PERFORMANCE AND ANALYSIS;

EID: 84893984952     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3286-3     Document Type: Article

References (49)

1. Arneric SP, Holladay M, Williams M (2007) Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol 74:1092-1101
2. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Deckersbach T, Kelly JF, Freudenreich O, Goff DC, Evins AE (2008) The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33:480-490
3. Bollini AM, Arnold MC, Keefe RS (2000) Test-retest reliability of the dot test of visuospatial working memory in patients with schizophrenia and controls. Schizophr Res 45:169-173
4. Buccafusco JJ, Terry AV, Jr, Decker MW, Gopalakrishnan M (2007) Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol 74:1202-1211
5. Burstein AH, Fullerton T, Clark DJ, Faessel HM (2006) Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol 46:1234-1240
6. Collins AC, Salminen O, Marks MJ, Whiteaker P, Grady SR (2009) The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handb Exp Pharmacol 192:85-112
7. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L (1988) The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res 26:223-238
8. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L (1989) The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res 29:65-85
9. Culhane MA, Schoenfeld DA, Barr RS, Cather C, Deckersbach T, Freudenreich O, Goff DC, Rigotti NA, Evins AE (2008) Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry 69:1743-1750
10. D'Souza MS, Markou A (2012) Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 62:1564-1573
11. Dunbar G, Boeijinga PH, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R (2007) Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 191:919-929
12. Eissenberg T, Griffiths RR, Stitzer ML (1996) Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology (Berl) 127:328-336
13. Esterlis I, Bois F, Pittman B, Picciotto MR, Shearer L, Carlson J, Niciu M, Cosgrove KP, D'Souza C (2013) In vivo evidence for B2-nAChR upregulation in smokers as compared to nonsmokers with schizophrenia. Society for Research on Nicotine and Tobacco, Boston
14. Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, Green MF, Schoenfeld DA, Rigotti NA, Goff DC (2005) Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry 66:1184-1190
15. Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH (2006) Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol 46:991-998
16. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94:587-592
17. George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten TR, Wexler BE (2002) Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26:75-85
18. Goldman-Rakic PS (1987) Circuitry of primate prefrontal cortex and regulation of behavior by representational memory Higher functions of the brain, part I, Handbook of physiology Section I: the nervous system. American Physiological Society, Bethesda, pp 374-417
19. Green MF (2006) Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67(Suppl 9):3-8. discussion 36-42
20. Hahn B, Sharples CG, Wonnacott S, Shoaib M, Stolerman IP (2003) Attentional effects of nicotinic agonists in rats. Neuropharmacology 44:1054-1067
21. Heishman SJ, Kleykamp BA, Singleton EG (2010) Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 210:453-469
22. Hennings EC, Kiss JP, Vizi ES (1997) Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices. Brain Res 759:292-294
23. Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A (2011) Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 68:1195-1206
24. Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE (2008) Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology (Berl) 199:89-98
25. Katner SN, Davis SA, Kirsten AJ, Taffe MA (2004) Effects of nicotine and mecamylamine on cognition in rhesus monkeys. Psychopharmacology (Berl) 175:225-240
26. Keefe RS, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DM, Davidson M, Davis KL (1995) A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res 17:25-33
27. Lansbergen MM, Kenemans JL, van Engeland H (2007) Stroop interference and attention-deficit/hyperactivity disorder: a review and meta-analysis. Neuropsychology 21:251-262
28. Levin ED, Wilson W, Rose JE, McEvoy J (1996) Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429-436
29. Levin ED, Conners CK, Silva D, Canu W, March J (2001) Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 9:83-90
30. Mathew SV, Law AJ, Lipska BK, Davila-Garcia MI, Zamora ED, Mitkus SN, Vakkalanka R, Straub RE, Weinberger DR, Kleinman JE, Hyde TM (2007) Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum Mol Genet 16:2921-2932
31. McClernon FJ, Rose JE (2005) Mecamylamine moderates cue-induced emotional responses in smokers. Addict Behav 30:741-753
32. Newhouse PA, Potter A, Corwin J, Lenox R (1994) Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10:93-107
33. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29-39
34. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW (2006) Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121-130
35. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-638
36. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C (2009) Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 65:144-149
37. Pickworth WB, Fant RV, Butschky MF, Henningfield JE (1997) Effects of mecamylamine on spontaneous EEG and performance in smokers and non-smokers. Pharmacol Biochem Behav 56:181-187
38. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA (1999) Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) 142:334-342
39. Rezvani AH, Kholdebarin E, Dawson E, Levin ED (2008) Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. Int J Neuropsychopharmacol 11:63-70
40. Rollema H, Hajos M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, Williams KE (2009) Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 78:813-824
41. Rose JE, Behm FM, Westman EC (2001) Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacol Biochem Behav 68:187-197
42. Rose JE, Behm FM, Westman EC, Bates JE (2003) Mecamylamine acutely increases human intravenous nicotine self-administration. Pharmacol Biochem Behav 76:307-313
43. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP (2005) Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62:649-659
44. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37:660-668
45. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327
46. Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S, Sershen H, Lajtha A (2009) Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 110:149-155
47. Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156:1931-1937
48. Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA (2006) ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 59:1065-1070
49. Winterer G (2010) Why do patients with schizophrenia smoke? Curr Opin Psychiatry 23:112-119